Pylarify injection
Ended Awarded Last action
- Contract number
- 36C24824N0316
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 8
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,457,923
Award facts
- Contract value 100% obligated
- $1,457,922.88 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$123,832 | |
| Funding Only Action | -$800,000 | |
| Original award | $2,381,755 |
About this award
Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., received a $1.46 million firm fixed-price Blanket Purchase Agreement (BPA) call from Veterans Integrated Service Network (VISN) 8 for the supply of PYLARIFY injection. PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer in patients. The contract, awarded on January 1, 2024, is set to be completed by March 12, 2025, with performance taking place in North Billerica, Massachusetts. This award represents a task order issued under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), and no set-aside designation was applied to this procurement.
The Department of Veterans Affairs, through VISN 8, utilizes BPA vehicles to efficiently procure critical radiopharmaceuticals and medical imaging products for VA medical centers across its network. Progenics Pharmaceuticals, as a specialized supplier of diagnostic imaging agents, maintains multiple significant indefinite delivery vehicles with the VA and Department of Defense Health Agency, with potential values ranging up to $290 million under the broader Federal Supply Schedule. This contract supports VA healthcare providers' ability to deliver advanced diagnostic imaging services for prostate cancer detection and other oncology-related diagnostic procedures across its medical facilities.
Quick answers
Who was awarded contract 36C24824N0316?
36C24824N0316 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 8 (Veterans Health Administration) on January 1, 2024.
How much is contract 36C24824N0316 worth?
The government has obligated $1,457,923 on 36C24824N0316.
Is contract 36C24824N0316 an order under another contract?
Yes. 36C24824N0316 is a BPA call under 36F79719D0170-36C24823A0018, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24824N0316 competed?
The extent of competition for 36C24824N0316 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award